AGIO vs. ROIV, INSM, ASND, LEGN, CERE, ITCI, VKTX, JAZZ, BPMC, and SMMT
Should you be buying Agios Pharmaceuticals stock or one of its competitors? The main competitors of Agios Pharmaceuticals include Roivant Sciences (ROIV), Insmed (INSM), Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), Cerevel Therapeutics (CERE), Intra-Cellular Therapies (ITCI), Viking Therapeutics (VKTX), Jazz Pharmaceuticals (JAZZ), Blueprint Medicines (BPMC), and Summit Therapeutics (SMMT). These companies are all part of the "pharmaceutical preparations" industry.
Roivant Sciences (NASDAQ:ROIV) and Agios Pharmaceuticals (NASDAQ:AGIO) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment, community ranking and earnings.
Roivant Sciences has a net margin of 3,484.86% compared to Roivant Sciences' net margin of -1,199.26%. Agios Pharmaceuticals' return on equity of -31.89% beat Roivant Sciences' return on equity.
Roivant Sciences presently has a consensus price target of $16.90, suggesting a potential upside of 63.13%. Agios Pharmaceuticals has a consensus price target of $35.00, suggesting a potential downside of 3.69%. Given Agios Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Roivant Sciences is more favorable than Agios Pharmaceuticals.
64.8% of Roivant Sciences shares are held by institutional investors. 4.6% of Roivant Sciences shares are held by insiders. Comparatively, 4.9% of Agios Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Roivant Sciences has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500.
In the previous week, Agios Pharmaceuticals had 3 more articles in the media than Roivant Sciences. MarketBeat recorded 20 mentions for Agios Pharmaceuticals and 17 mentions for Roivant Sciences. Agios Pharmaceuticals' average media sentiment score of 0.42 beat Roivant Sciences' score of 0.39 indicating that Roivant Sciences is being referred to more favorably in the media.
Agios Pharmaceuticals received 435 more outperform votes than Roivant Sciences when rated by MarketBeat users. However, 75.44% of users gave Roivant Sciences an outperform vote while only 67.51% of users gave Agios Pharmaceuticals an outperform vote.
Agios Pharmaceuticals has lower revenue, but higher earnings than Roivant Sciences. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.
Summary
Roivant Sciences beats Agios Pharmaceuticals on 13 of the 18 factors compared between the two stocks.
Get Agios Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AGIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Agios Pharmaceuticals Competitors List
Related Companies and Tools
